View all the latest information in graft-versus-host disease, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Novel drugs for treating cGvHD: Phase I results of axatilimab for heavily pretreated patients
Second line or further lines of therapy represent an unmet need in treating patients with chronic...
High- vs low-dose antithymocyte globulin for pediatric patients with leukemia undergoing allo-PBSCT
A study by Hyun Mi Kang et al. investigated the effects of different ATG dosages on the overall...
Novel drugs for treating cGvHD: preliminary phase I/II results for baricitinib
Chronic graft-versus-host disease (cGvHD) is associated with organ function impairment, shorter survival, and immune...
REACH3 study: Should ruxolitinib become SoC for steroid-dependent or refractory chronic GvHD?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to...
Is the microbiota biotherapeutic MaaT013 a safe and effective option for steroid-refractory GI GvHD?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub...
What is the evidence that fecal microbiota transplantation can cure GvHD?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Mette Hazenberg,...
Can the antigen-specific CD8+ T-cell product Nexi-001 be safely and effectively applied in patients?
Review of oral and gut microbiome signatures in allo-HSCT-associated aGvHD
Micaela Beckman and team, in their systematic review published in Supportive Care in Cancer, using conventional literature...
Mesenchymal stromal cells
Chemokine receptor antagonists
Fecal microbiota transplant
Nuclear receptor agonists